Technologies
This technology is a monoclonal antibody that can isolate low-density lipoprotein receptor-related protein 1 (LRP1) from biological tissue for use in therapies for neurodegenerative diseases.
Low-density lipoprotein receptor-related protein 1 (LRP1) is an important protein implicated in the development of brain plaques in neurodegenerative diseases, with roles in the uptake and regulation of other proteins that create plaques on the brain and reduce cognitive function. Although LRP1 is critical for preventing the development of these plaques, there are currently no methods to genetically engineer LRP1 for therapeutic use. Current methods for the purification of LRP1 use in vitro expression systems, which are expensive and have limited yield. There is a need for a method for purifying LRP1 to enable large-scale production of LRP1 across different hosts for the development of therapeutics for treating neurodegenerative diseases.
This technology is a monoclonal antibody that targets low-density lipoprotein receptor-related protein 1 (LRP1). It allows for the isolation of the LRP1 receptor using immunoaffinity chromatography. This monoclonal antibody targets a conserved epitope on LRP1, allowing for purification from different species, including human, bovine, and murine tissues. This technology has the potential to improve research in and treatments of currently incurable neurodegenerative diseases by producing larger quantities of LRP1 across different host species.
IR CU25221
Licensing Contact: Kristin Neuman